Research ArticleOriginal Article
Open Access

Epidemiology of Clostridioides difficile infection at a tertiary care facility in Saudi Arabia

Results of prospective surveillance

Naoufel M. Kaabia, Hanadi Al Basha, Dalal A. Bukhari, Nabiha Bouafia, Aeshah N. Al Qahtani, Ahmad M. Alshahrani, Ismail M. Aboushanab and Abdulrahman N. Al Odayani
Saudi Medical Journal February 2024, 45 (2) 188-193; DOI: https://doi.org/10.15537/smj.2024.45.2.20230398

References

  1. 1.↵
    1. Burke KE,
    2. Lamont JT.
    Clostridium difficile infection: a worldwide disease. Gut Liver 2014; 8: 1-6.
    OpenUrlCrossRefPubMed
  2. 2.↵
    CDC. Antibiotic resistance threats in the United States, 2019. [Updated 2020; 2023 Sep]. Available from: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
  3. 3.↵
    1. Lessa FC,
    2. Mu Y,
    3. Bamberg WM,
    4. Beldavs ZG,
    5. Dumyati GK,
    6. Dunn JR, et al.
    Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372: 825-834.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Eze P,
    2. Balsells E,
    3. Kyaw MH,
    4. Nair H.
    Risk factors for Clostridium difficile infections - an overview of the evidence base and challenges in data synthesis. J Glob Health 2017; 7: 010417.
    OpenUrl
  5. 5.↵
    1. Azab M,
    2. Doo L,
    3. Doo DH,
    4. Elmofti Y,
    5. Ahmed M,
    6. Cadavona JJ, et al.
    Comparison of the hospital-acquired Clostridium difficile infection risk of using proton pump inhibitors versus histamine-2 receptor antagonists for prophylaxis and treatment of stress ulcers: a systematic review and meta-analysis. Gut Liver 2017; 11: 781-788.
    OpenUrl
  6. 6.↵
    1. McDonald EG,
    2. Milligan J,
    3. Frenette C,
    4. Lee TC.
    Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection. JAMA Intern Med 2015; 175: 784-791.
    OpenUrl
  7. 7.↵
    1. Büchler AC,
    2. Rampini SK,
    3. Stelling S,
    4. Ledergerber B,
    5. Peter S,
    6. Schweiger A, et al.
    Antibiotic susceptibility of Clostridium difficile is similar worldwide over 2 decades despite widespread use of broad-spectrum antibiotics: an analysis carried out at the University Hospital of Zurich. BMC Infect Dis 2014; 14: 607.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Mullish BH,
    2. Williams HR.
    Clostridium difficile infection and antibiotic-associated diarrhoea. Clin Med (Lond) 2018; 18: 237-241.
    OpenUrlCrossRef
  9. 9.↵
    1. Slimings C,
    2. Riley TV.
    Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014; 69: 881-891.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Alalawi M,
    2. Aljahdali S,
    3. Alharbi B,
    4. Fagih L,
    5. Fatani R,
    6. Aljuhani O.
    Clostridium difficile infection in an academic medical center in Saudi Arabia: prevalence and risk factors. Ann Saudi Med 2020; 40: 305-309.
    OpenUrl
  11. 11.↵
    NHSN. Multidrug-resistant organism and Clostridioides difficile infection (MDRO/CDI) module. [Updated 2024; accessed date?]. Available from: https://www.cdc.gov/nhsn/pdfs/pscmanual/12pscmdro_cdadcurrent.pdf
  12. 12.↵
    1. Aljafel NA,
    2. Al-Shaikhy HH,
    3. Alnahdi MA,
    4. Thabit AK.
    Incidence of Clostridioides difficile infection at a Saudi tertiary academic medical center and compliance with IDSA/SHEA, ACG, and ESCMID guidelines for treatment over a 10-year period. J Infect Public Health 2020; 13: 1156-1160.
    OpenUrl
  13. 13.↵
    1. Sue ES,
    2. Mohammed FH,
    3. Michael A.
    Prevalence of Clostridium difficile toxin in diarrhea stool samples of patients from a general hospital in Eastern province, Saudi Arabia. Int J Med Res Health Sci 2014; 3: 302-308.
    OpenUrl
  14. 14.↵
    1. Dudeck MA,
    2. Weiner LM,
    3. Malpiedi PJ,
    4. Edwards JR,
    5. Peterson KD,
    6. Sievert DM.
    Risk adjustment for healthcare facility-onset C. difficile and MRSA bacteremia laboratory-identified event reporting in NHSN. [Updated 2013; 2023 Sep]. available from: https://www.cdc.gov/nhsn/pdfs/mrsa-cdi/riskadjustment-mrsa-cdi.pdf
  15. 15.↵
    1. Alzouby S,
    2. Baig K,
    3. Alrabiah F,
    4. Shibl A,
    5. Al-Nakhli D,
    6. Senok AC.
    Clostridioides difficile infection: incidence and risk factors in a tertiary care facility in Riyadh, Saudi Arabia. J Infect Public Health 2020; 13: 1012-1017.
    OpenUrl
  16. 16.↵
    1. Al-Tawfiq JA,
    2. Abed MS.
    Clostridium difficile-associated disease among patients in Dhahran, Saudi Arabia. Travel Med Infect Dis 2010; 8: 373-376.
    OpenUrlPubMed
  17. 17.↵
    1. Al-Tawfiq JA,
    2. Rabaan AA,
    3. Bazzi AM,
    4. Raza S,
    5. Noureen M.
    Clostridioides (Clostridium) difficile-associated disease: epidemiology among patients in a general hospital in Saudi Arabia. Am J Infect Control 2020; 48: 1152-1157.
    OpenUrl
  18. 18.↵
    1. Tawam D,
    2. Baladi M,
    3. Jungsuwadee P,
    4. Earl G,
    5. Han J.
    The positive association between proton pump inhibitors and Clostridium difficile infection. Innov Pharm 2021; 12: 10.24926/iip.v12i1.3439.
  19. 19.↵
    1. Van Werkhoven CH,
    2. van der Tempel J,
    3. Jajou R,
    4. Thijsen SF,
    5. Diepersloot RJ,
    6. Bonten MJ, et al.
    Identification of patients at high risk for Clostridium difficile infection: development and validation of a risk prediction model in hospitalized patients treated with antibiotics. Clin Microbiol Infect 2015; 21: 786.
    OpenUrl
  20. 20.↵
    1. Tabak YP,
    2. Srinivasan A,
    3. Yu KC,
    4. Kurtz SG,
    5. Gupta V,
    6. Gelone S, et al.
    Hospital-level high-risk antibiotic use in relation to hospital-associated Clostridioides difficile infections: retrospective analysis of 2016-2017 data from US hospitals. Infect Control Hosp Epidemiol 2019; 40: 1229-1235.
    OpenUrl
  21. 21.↵
    1. Brown KA,
    2. Fisman DN,
    3. Moineddin R,
    4. Daneman N.
    The magnitude and duration of Clostridium difficile infection risk associated with antibiotic therapy: a hospital cohort study. PLoS One 2014; 9: e105454.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Slimings C,
    2. Riley TV.
    Antibiotics and healthcare facility-associated Clostridioides difficile infection: systematic review and meta-analysis 2020 update. J Antimicrob Chemother 2021; 76: 1676-1688.
    OpenUrl
  23. 23.↵
    1. Vardakas KZ,
    2. Trigkidis KK,
    3. Boukouvala E,
    4. Falagas ME.
    Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. Int J Antimicrob Agents 2016; 48: 1-10.
    OpenUrlCrossRef
  24. 24.↵
    1. Dingle KE,
    2. Didelot X,
    3. Quan TP,
    4. Eyre DW,
    5. Stoesser N,
    6. Golubchik T, et al.
    Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet Infect Dis 2017; 17: 411-421.
    OpenUrlPubMed
  25. 25.↵
    1. Roncarati G,
    2. Dallolio L,
    3. Leoni E,
    4. Panico M,
    5. Zanni A,
    6. Farruggia P.
    Surveillance of Clostridium difficile infections: results from a 6-year retrospective study in 9 hospitals of a North Italian local health authority. Int J Environ Res Public Health 2017; 14: 61.
    OpenUrl
  26. 26.↵
    1. Kurti Z,
    2. Lovasz BD,
    3. Mandel MD,
    4. Csima Z,
    5. Golovics PA,
    6. Csako BD, et al.
    Burden of Clostridium difficile infection between 2010 and 2013: trends and outcomes from an academic center in Eastern Europe. World J Gastroenterol 2015; 21: 6728-6735.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords